Skip to content

Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible for Intensive Autologous Stem Cell Transplantation Treatment

Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible for Intensive Autologous Stem Cell Transplantation Treatment (PREHAB-APA)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06789003
Acronym
PREHAB-APA
Enrollment
120
Registered
2025-01-23
Start date
2025-02-10
Completion date
2028-02-28
Last updated
2026-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

Adapted Physical Activity, Autologous stem cell transplantation, Quality of Life, Fatigue

Brief summary

Adapted physical activity for patients with haematological malignancies generally has positive effects on quality of life, fatigue and physical condition. However, some studies show little or no effect. This may be explained by inefficient protocols, but also by low rates of patient acceptability regarding the proposed exercises. The multiplicity of APA protocols and the fluctuation of their results mean that validity, methodology and effects on patients need to be verified before they can be considered for implementation in healthcare services. A program must prove its feasibility, but patients must also adhere to it. Acceptability can be measured by adherence, which represents the number of validated sessions in relation to the number of planned sessions, and by attrition, which corresponds to the number of stops or drop-outs for any reason. The various APA programs offered in the context of intensive auto or allograft treatment are limited, notably by adherence, which can fall by as much as 24%, and attrition, which can be as high as 67%. Optimization of the proposed exercises and follow-up methods is therefore necessary in order to propose an APA program that will be feasible, effective and acceptable to a maximum number of patients. To meet these objectives for patients with multiple myeloma eligible for autologous stem cell transplantation, the protocol for this study took into consideration the various recommendations of previous publications and the guidelines from HAS (French National Authority for Health). The ultimate goal of this study is to validate, in terms of effectiveness and acceptability, the methodology and in particular the use of new specific tools for optimizing an APA program. It will subsequently be offered to all patients with multiple myeloma eligible for autologous stem cell transplantation, independently of their age or physical condition, while respecting their rhythm and physical condition.

Interventions

OTHERAdapted exercises

Patients will have 3 sessions a week: 1 strengthening session and 2 endurance sessions. For each session, patients will choose the exercises to be performed from the exercise booklet or the videos and records their observations in the patient notebook. Depending on the treatment plan, patients will have alternating supervised (in hospital) and unsupervised (at home) APA sessions, in order to follow the rhythm of their visits to the department. Each session will last 45 minutes with a medium intensity according to the Borg scale.

OTHERNo intervention

Patients will not be practising adapted exercises as part of the study. They will be treated with chemotherapy according to standard practice.

BEHAVIORALQuality of Life questionnaire

QoL questionnaire (EORTC QLQ-C30) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation

BEHAVIORALQuestionnaire of Fatigue

Questionnaire (EORTC QLQ-FA12) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation

Questionnaire (IPAQ) at baseline and after transplantation

BEHAVIORALPhysical condition

Evaluation of physical condition at baseline, mid term (after 2 cycles of chemotherapy), before transplantation and after transplantation

Sponsors

Centre Hospitalier Henri Duffaut - Avignon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years old. * CML patient in chronic phase, eligible for oral therapy. * Diagnosis of multiple myeloma. * Patient eligible for autologous stem cell transplantation. * Patient capable to read, understand and complete a questionnaire in french. * WHO less than or equal to 2. * Patient affiliated with french social security. * Patient with a medical prescription for APA.

Exclusion criteria

* Patient with previous cancer within the previous 3 years (except basal cell and squamous cell skin cancers, carcinomas in situ of any type that have been previously resected, and stable prostate or breast cancers more than 3 years old and undergoing adjuvant hormone therapy). * Medical contraindications to APA (heart failure, angina, unbalanced hypertension, bone metastases, severe osteoporosis, etc.) * Sensory or motor neuropathy. * Patient deprived of liberty, under guardianship or curatorship. * Patient considered socially or psychologically unfit to be enrolled in a study.

Design outcomes

Primary

MeasureTime frameDescription
1. Evaluate the effect of the APA program on fatigue status.Baseline, mid-term assessment (after 2 cycles of chemotherapy, each cycle has a duration of 21 days), assessment before transplant and assessment after transplant (on average about 30 weeks after inclusion)Cancer Related Fatigue : EORTC QLQ-FA12 questionnaire (minimum = 0, maximum = 100, higher score means better outcome).

Secondary

MeasureTime frameDescription
Evaluate the effect of the APA program on quality of life.Baseline, mid-term assessment (after 2 cycles of chemotherapy, each cycle has a duration of 21 days), assessment before transplant and assessment after transplant (on average about 30 weeks after inclusion)Quality of Life of Cancer Patients : EORTC QLQ-C30 questionnaire (minimum = 0, maximum = 100, higher score means better outcome).
Fitness assessment.Baseline, mid-term assessment (after 2 cycles of chemotherapy, each cycle has a duration of 21 days), assessment before transplant and assessment after transplant (on average about 30 weeks after inclusion)6-minute walk test.
Nutritional status.Baseline, mid-term assessment (after 2 cycles of chemotherapy, each cycle has a duration of 21 days), assessment before transplant and assessment after transplant (on average about 30 weeks after inclusion)BMI.
Grade III-IV adverse events rate.From inclusion to assessment after transplant (on average about 30 weeks after inclusion)According to Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Comparison of hospitalization length.Assessment after transplant (on average about 30 weeks after inclusion)Hospitalization time (in days) after autologous stem cell transplantation.
15. Attraction to sport assessment.Assessment after transplant (on average about 30 weeks after inclusion)IPAQ questionnaire (continuous score expressed as MET-min per week: MET level x minutes of activity/day x days per week, higher score means better outcome)
Adherence rate.Assessment after transplant (on average about 30 weeks after inclusion)Percentage of patients who participated and validated more than 66 percent of the APA sessions recommended by the program.
Attrition rate.Assessment after transplant (on average about 30 weeks after inclusion)Percentage of patients who discontinued the program during the course of the study among patients who received an autologous stem cell transplantation.
Rate of effective APA sessions.Assessment after transplant (on average about 30 weeks after inclusion)Number of validated APA sessions divided by the number of planned sessions.
Reasons for discontinuing the APA program.Assessment after transplant (on average about 30 weeks after inclusion)Self-reported reasons for discontinuation
Patient's comments and remarks.100 days after transplantPatient's follow-up notebook.
Patient satisfaction.100 days after transplantSatisfaction questionnaire. Likert-type scale (minimum = 0, maximum = 4, higher score means better outcome).

Countries

France

Contacts

CONTACTMarilyne Grinand, PhD
grinand.marilyne@ch-avignon.fr(+33)432759392
CONTACTEmmanuelle Guilie, APA
guilie.emmanuelle@ch-avignon.fr(+33)432759300

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026